FIGURE 3 CALGB (Cancer and Leukemia Group B) 9221: Fatigue, dyspnea, and physical functioning, as recorded on the EORTC (European Organization for Research and Treatment of Cancer) questionnaire, of patients with myelodysplastic syndrome who crossed over from supportive care to treatment with azacitidine (5-Aza-C) (n = 30)
From the following article:
Methylation inhibitor therapy in the treatment of myelodysplastic syndrome
Lewis R Silverman and Ghulam J Mufti
BACK TO ARTICLE
Figure 3. CALGB (Cancer and Leukemia Group B) 9221: Fatigue, dyspnea, and physical functioning, as recorded on the EORTC (European Organization for Research and Treatment of Cancer) questionnaire, of patients with myelodysplastic syndrome who crossed over from supportive care to treatment with azacitidine (5-Aza-C) (n = 30)
*Higher scores indicate better functioning. **Lower scores indicate symptom improvement. From Kornblith AB et al. (2002) Impact of azacitidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 20: 2441–2452. Reprinted with permission from the American Society of Clinical Oncology.
